These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9862681)

  • 21. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.
    Yang G; Mizuno MT; Hellström KE; Chen L
    J Immunol; 1997 Jan; 158(2):851-8. PubMed ID: 8993003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
    J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
    Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
    J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid induction of CD95 ligand and CD4+ T cell-mediated apoptosis by CD137 (4-1BB) costimulation.
    Ebata T; Mogi S; Hata Y; Fujimoto JI; Yagita H; Okumura K; Azuma M
    Eur J Immunol; 2001 May; 31(5):1410-6. PubMed ID: 11465097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Requirements for CD28-dependent T cell-mediated cytotoxicity.
    Azuma M; Cayabyab M; Phillips JH; Lanier LL
    J Immunol; 1993 Mar; 150(6):2091-101. PubMed ID: 8383716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B7-1 induces immunosuppression when expressed in cultured neonatal mice keratinocytes.
    Nengwen K; Li F; Li X; Juan S; Jianjun L; Chuntao Z; Youping L
    Immunobiology; 2009; 214(8):653-63. PubMed ID: 19249124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triggering of murine NK cells by CD40 and CD86 (B7-2).
    Martín-Fontecha A; Assarsson E; Carbone E; Kärre K; Ljunggren HG
    J Immunol; 1999 May; 162(10):5910-6. PubMed ID: 10229827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule.
    La Motte RN; Rubin MA; Barr E; Leiden JM; Bluestone JA; Mokyr MB
    Cancer Immunol Immunother; 1996 Mar; 42(3):161-9. PubMed ID: 8640844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation.
    Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G
    Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
    Chung SW; Cohen EP; Kim TS
    Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B7.1 immunogene therapy effectively activates CD(4+) tumor-infiltrating lymphocytes in the central nervous system in comparison with B7.2 gene therapy.
    Ando H; Saio M; Ohe N; Tamakawa N; Yu H; Nakayama T; Yoshimura S; Kaku Y; Iwama T; Shinoda J; Sakai N; Takami T
    Int J Oncol; 2002 Apr; 20(4):807-12. PubMed ID: 11894129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection.
    Rakhmilevich AL
    Transplantation; 1994 Jul; 58(1):72-80. PubMed ID: 7913562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
    Dye ES
    J Immunol; 1986 Feb; 136(4):1510-5. PubMed ID: 3080526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor.
    Fioretti F; Fradelizi D; Stoppacciaro A; Ramponi S; Ruco L; Minty A; Sozzani S; Garlanda C; Vecchi A; Mantovani A
    J Immunol; 1998 Jul; 161(1):342-6. PubMed ID: 9647242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.